Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 321

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 321
---

difficulties in managing this growth, which could disrupt our operations.

We anticipate expanding our roster of full-time employees, which
will require significant management time and attention to hire qualified employees, which will divert a disproportionate amount of attention
away from our daily operations and dedicate significant time to overseeing these growth initiatives. We will face challenges in effectively
managing the expansion of our operations, which could lead to operational errors, missed business prospects, employee attrition, and decreased
productivity among those who remain. Anticipated growth could necessitate substantial capital investments and potentially divert financial
resources from other projects, including the advancement of additional product candidates. If our management team struggles to manage
our growth effectively, it could lead to higher-than-expected expenses, curtailed revenue generation and growth capabilities, and
potential obstacles in executing our business strategy. The success of our future financial performance and our ability to effectively
bring product candidates to market and maintain competitiveness will hinge, in part, on our capacity to adeptly manage any forthcoming
expansion.

Risks Related to the Company’s Requirements for Additional
Capital

The following risk factors reference the risks and uncertainties
relating to additional capital requirements of OSR, which, following the closing of the Business Combination, will be the additional capital
requirements of the Company. References in this section to “we,” “us,” and “our” refer to OSR prior
to the closing of the Business Combination and to the Company after closing.

We will require substantial additional capital to finance our
operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate
one or more of our research and drug development programs, future commercialization efforts and/or other operations.

Developing pharmaceutical products, including conducting preclinical
studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years. OSR’s operations,
through its subsidiaries, have consumed substantial amounts of cash since inception. We currently do not have sufficient committed sources
of additional capital to fund our current development plans. We expect our expenses to increase in connection with our ongoing activities,
particularly as we advance our preclinical and clinical development programs, seek regulatory approvals for our product candidates, and
launch and commercialize any products for which we receive regulatory approval. We also expect to incur additional costs associated with
operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to implement our current